论文部分内容阅读
目的观察不同剂量补锌疗法治疗轮状病毒肠炎低锌儿童的临床疗效和安全性,分析其最佳使用剂量。方法采用前瞻性研究方法,将94名轮状病毒肠炎低锌儿童随机分为常规治疗对照组,在此基础上口服高、中、低剂量的葡萄糖酸锌颗粒共4组。观察各组患者的止泻时间、大便次数和性状复常时间、退热时间、呕吐停止时间及血清锌水平,并对比两组患者的临床疗效。结果中剂量组的有效率明显高于对照组(P<0.05),低剂量组与对照组之间、高剂量组与中剂量组之间差异均无统计学意义(P>0.05)。低剂量组患儿的止泻时间、大便次数和性状、脱水复常时间均明显低于对照组,血清锌水平明显高于对照组;同时,中剂量组患儿的止泻时间、大便次数和性状、脱水复常时间均明显低于低剂量组,血清锌水平明显高于低剂量组,其差异均有统计学意义(P<0.05);然高剂量组各症状及血清锌水平与中剂量组无统计学差异(P>0.05),且呕吐停止时间明显延长(P<0.05)。结论治疗轮状病毒肠炎低锌儿童,过多的锌可能造成胃肠负担,应合理控制补充剂量。
Objective To observe the clinical efficacy and safety of different doses of zinc supplementation in the treatment of children with rotavirus enteritis and low zinc, and to analyze the optimal dosage. Methods A total of 94 low-zinc enteritis children with rotavirus enteritis were randomly divided into conventional treatment group and control group. A total of 94 oral zinc gluconate granules were orally administrated. The anti-diarrhea time, stool frequency and recovery time, antipyretic time, vomiting stop time and serum zinc level were observed in each group. The clinical efficacy was compared between the two groups. Results The effective rate of middle dose group was significantly higher than that of control group (P <0.05). There was no significant difference between low dose group and control group, high dose group and middle dose group (P> 0.05). The antidiarrheal time, stool frequency and traits, dehydration and rehydration time in low dose group were significantly lower than those in control group, serum zinc level was significantly higher than that in control group. Meanwhile, the diarrhea time, stool frequency, (P <0.05). However, the symptoms and the level of serum zinc in the high-dose group were significantly lower than those in the low-dose group and the serum zinc levels were significantly higher than those in the low-dose group There was no significant difference between the two groups (P> 0.05), and the vomiting stop time was significantly prolonged (P <0.05). Conclusion Treatment of rotavirus enteritis in children with low zinc, excessive zinc may cause gastrointestinal burden, should be a reasonable dose control.